Literature DB >> 7714546

p53 immunoreactivity in oligodendrogliomas.

J Pavelić1, V Hlavka, M Poljak, N Gale, K Pavelić.   

Abstract

Data are presented on p53 protein presence in human oligodendrogliomas whose progress from low grade to anaplastic oligodendroglioma can be followed. Expression was evaluated by formalin-fixed paraffin-embedded section immunohistochemistry, using monoclonal PAb 1801 antibody. The frequency of p53 protein accumulation is related to the stage of tumor malignancy. All the samples (100%) of malignant oligodendrogliomas were positive for p53 protein. Of 14 type II oligodendroglioma samples, 9 were positive (64%) while among type I oligodendroglioma the positivity was 28%. The mean proportion of reactive cells was also higher in malignant oligodendrogliomas. However, mean intensity staining did not differ among various grades of tumors. Our results point to the direct link between p53 protein accumulation and the malignant stage of human oligodendrogliomas. However, the value of p53 protein accumulation in predicting malignant behavior of oligodendrogliomas requires further confirmation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7714546     DOI: 10.1007/bf01058349

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  24 in total

1.  p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia.

Authors:  G Gaidano; P Ballerini; J Z Gong; G Inghirami; A Neri; E W Newcomb; I T Magrath; D M Knowles; R Dalla-Favera
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-15       Impact factor: 11.205

2.  The meaning of the concept of the "transitional" group of oligodendrogliomas (a pathological and histochemical study).

Authors:  V Hlavka; I Jelicić; P Miklić
Journal:  Acta Med Iugosl       Date:  1985

3.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

4.  Mitotic recombination of chromosome 17 in astrocytomas.

Authors:  C D James; E Carlbom; M Nordenskjold; V P Collins; W K Cavenee
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

Review 5.  The new WHO classification of brain tumours.

Authors:  P Kleihues; P C Burger; B W Scheithauer
Journal:  Brain Pathol       Date:  1993-07       Impact factor: 6.508

6.  p53 protein immunostaining in routinely processed paraffin-embedded sections.

Authors:  J M Bruner; J H Connelly; H Saya
Journal:  Mod Pathol       Date:  1993-03       Impact factor: 7.842

Review 7.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

8.  Distribution of p53 protein expression in gliosarcomas: an immunohistochemical study.

Authors:  S Albrecht; J H Connelly; J M Bruner
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

9.  p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression.

Authors:  D Fults; D Brockmeyer; M W Tullous; C A Pedone; R M Cawthon
Journal:  Cancer Res       Date:  1992-02-01       Impact factor: 12.701

10.  p53 mutations in human lung tumors.

Authors:  C W Miller; K Simon; A Aslo; K Kok; J Yokota; C H Buys; M Terada; H P Koeffler
Journal:  Cancer Res       Date:  1992-04-01       Impact factor: 12.701

View more
  4 in total

1.  The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma. An analysis of 91 cases.

Authors:  A Korshunov; A Golanov
Journal:  J Neurooncol       Date:  2000-05       Impact factor: 4.130

2.  Cell cycle regulators (p21, p53, pRb) in oligodendrocytic tumors: a study by novel tumor microarray technique.

Authors:  H E Miettinen; N Paunu; I Rantala; H Kalimo; L Paljärvi; H Helin; H Haapasalo
Journal:  J Neurooncol       Date:  2001-10       Impact factor: 4.130

3.  Proliferation and apoptosis in long-term surviving low grade gliomas in relation to radiotherapy.

Authors:  Mart A A M Heesters; Jan Koudstaal; K Gwan Go; Willemina M Molenaar
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

4.  Immunohistochemical markers for prognosis of oligodendroglial neoplasms.

Authors:  Andrey Korshunov; Andrey Golanov; Regina Sycheva
Journal:  J Neurooncol       Date:  2002-07       Impact factor: 4.130

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.